ILD Day: Recent updates in treatment, management of interstitial lung disease

Sept. 14 marks the second annual ILD Day, which aims to increase awareness of interstitial lung diseases.

There are more than 200 causes of ILD. Over 50,000 cases of ILD are diagnosed each year in the United States, with more than 250,000 people living with pulmonary fibrosis and ILD, according to the Pulmonary Fibrosis Foundation.

ILD Day is held on the second Wednesday in September and is a collaboration between the Pulmonary Fibrosis Foundation, Arthritis Foundation, Foundation for Sarcoidosis Research, The Myositis Association, PF Warriors, Scleroderma Foundation, Scleroderma Research Foundation, Sjögren’s Foundation and Wescoe Foundation for Pulmonary Fibrosis.

For ILD Day, the Healio Editors compiled recent news on interstitial lung disease.

Children’s interstitial lung disease tied to high utilization of health care services

Children’s ILDs were associated with high utilization of health care services in European countries and subsequent economic burden on health systems, researchers reported in Thorax. Read more

Environmental exposures common in people with pulmonary fibrosis

Among individuals with familial pulmonary fibrosis, environmental exposures are common, vary by sex and influence the CT pattern, timing of disease onset and mortality. Read more

Trajectory of lung function ‘varies considerably’ after ILD diagnosis

It is important to consider ILD subtypes when applying progressive fibrosing ILD criteria, researchers concluded in an analysis published in European Respiratory Journal. Read more

One-third of patients with rheumatoid arthritis-associated ILD experience acute exacerbation

In a new study in Chest, the incidence of acute exacerbation was nearly one-third in patients with rheumatoid arthritis-associated ILD. Read more

Concomitant medication burden may impact tolerability of antifibrotic therapy in IPF

Concomitant medication burden is associated with antifibrotic medication intolerance among patients with idiopathic pulmonary fibrosis, according to research published in Annals of the American Thoracic Society. Read more

FDA approves inhaled treprostinil for treatment of PAH, pulmonary hypertension-ILD

ATS issues new clinical practice guideline on IPF, progressive fibrotic ILDs

SAN FRANCISCO — A session at the American Thoracic Society International Conference highlighted a new clinical practice guideline addressing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults. Read more

Acute exacerbation most frequent cause of death in patients with rheumatoid arthritis-ILD, IPF

The most frequent cause of death in patients with rheumatoid arthritis-associated ILD and also those with idiopathic pulmonary fibrosis is acute exacerbation, researchers reported. Read more